Co-Authors
This is a "connection" page, showing publications co-authored by M Nguyen and Cornelius Clancy.
Connection Strength
10.911
-
Bacterial Superinfections Among Persons With Coronavirus Disease 2019: A Comprehensive Review of Data From Postmortem Studies. Open Forum Infect Dis. 2021 Mar; 8(3):ofab065.
Score: 0.928
-
Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect? Clin Infect Dis. 2020 12 17; 71(10):2736-2743.
Score: 0.919
-
A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals. Open Forum Infect Dis. 2021 Feb; 8(2):ofaa617.
Score: 0.919
-
PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates. JAC Antimicrob Resist. 2020 Sep; 2(3):dlaa049.
Score: 0.893
-
Diagnosing Invasive Candidiasis. J Clin Microbiol. 2018 05; 56(5).
Score: 0.765
-
Diagnosing candidemia with the T2Candida panel: an instructive case of septic shock in which blood cultures were negative. Diagn Microbiol Infect Dis. 2019 Jan; 93(1):54-57.
Score: 0.762
-
T2 magnetic resonance for the diagnosis of bloodstream infections: charting a path forward. J Antimicrob Chemother. 2018 03 01; 73(suppl_4):iv2-iv5.
Score: 0.757
-
Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences. J Fungi (Basel). 2018 Feb 19; 4(1).
Score: 0.756
-
Invasive Candidiasis in Various Patient Populations: Incorporating Non-Culture Diagnostic Tests into Rational Management Strategies. J Fungi (Basel). 2016 Feb 06; 2(1).
Score: 0.656
-
Impact of the Coronavirus Disease 2019 Pandemic on Outpatient Antibiotic Prescriptions in the United States. Open Forum Infect Dis. 2020 Dec; 7(12):ofaa575.
Score: 0.230
-
Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter. Antimicrob Agents Chemother. 2020 10 20; 64(11).
Score: 0.227
-
Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19. Open Forum Infect Dis. 2020 Jul; 7(7):ofaa242.
Score: 0.222
-
How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. Clin Infect Dis. 2019 02 15; 68(5):850-853.
Score: 0.202
-
Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. Antimicrob Agents Chemother. 2018 12; 62(12).
Score: 0.199
-
Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance. Antimicrob Agents Chemother. 2018 08; 62(8).
Score: 0.195
-
Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. Clin Infect Dis. 2018 05 17; 66(11):1678-1686.
Score: 0.192
-
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother. 2018 05; 62(5).
Score: 0.191
-
Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol. 2018 02; 56(2).
Score: 0.188
-
Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017 09; 61(9).
Score: 0.183
-
Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. Antimicrob Agents Chemother. 2017 09; 61(9).
Score: 0.183
-
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017 08; 61(8).
Score: 0.182
-
Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature. Open Forum Infect Dis. 2017; 4(3):ofx101.
Score: 0.181
-
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. Clin Infect Dis. 2017 07 01; 65(1):110-120.
Score: 0.181
-
Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum ß-Lactamases. Antimicrob Agents Chemother. 2017 05; 61(5).
Score: 0.178
-
In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases. Antimicrob Agents Chemother. 2017 05; 61(5).
Score: 0.178
-
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother. 2017 03; 61(3).
Score: 0.176
-
Characterising the post-antifungal effects of micafungin against Candida albicans, Candida glabrata, Candida parapsilosis and Candida krusei isolates. Int J Antimicrob Agents. 2010 Jan; 35(1):80-4.
Score: 0.106
-
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Med. 2021 08; 47(8):819-834.
Score: 0.060
-
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. 2020 Aug; 46(8):1524-1535.
Score: 0.056
-
Efficacy of T2 Magnetic Resonance Assay in Monitoring Candidemia after Initiation of Antifungal Therapy: the Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) Trial. J Clin Microbiol. 2018 04; 56(4).
Score: 0.048